First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting ...
(RTTNews) - Kite, a Gilead Company (GILD), announced the primary overall survival analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta ...
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study Axicabtagene ciloleucel (axi-cel) is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results